First Time Loading...

Vita Life Sciences Ltd
ASX:VLS

Watchlist Manager
Vita Life Sciences Ltd Logo
Vita Life Sciences Ltd
ASX:VLS
Watchlist
Price: 2.22 AUD 6.73% Market Closed
Updated: May 15, 2024
Section:
 

Relative Value

The Relative Value of one VLS stock under the Base Case scenario is 1.9 AUD. Compared to the current market price of 2.22 AUD, Vita Life Sciences Ltd is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VLS Relative Value
Base Case
1.9 AUD
Overvaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
22
vs Industry
60
Median 3Y
1.4
Median 5Y
1.2
Industry
2.5
More Details
13.2
P/E
P/E
Price to Earnings
13.2
vs History
34
vs Industry
34
Median 3Y
11.9
Median 5Y
11.6
Industry
23.4
More Details
9.2
P/OCF
P/OCF
Price to OCF
9.2
vs History
73
vs Industry
38
Median 3Y
13.7
Median 5Y
13.7
Industry
17.9
More Details
9.8
P/FCFE
P/FCFE
Price to FCFE
9.8
vs History
76
vs Industry
30
Median 3Y
17.4
Median 5Y
17.4
Industry
24.1
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
25
vs Industry
29
Median 3Y
2.5
Median 5Y
2.2
Industry
2.1
More Details
1.3
EV/S
EV/S
Enterprise Value to Sales
1.3
vs History
23
vs Industry
66
Median 3Y
1.1
Median 5Y
1
Industry
2.6
More Details
2.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.2
vs History
23
vs Industry
70
Median 3Y
1.9
Median 5Y
1.6
Industry
5.2
More Details
7.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.8
vs History
34
vs Industry
40
Median 3Y
6.6
Median 5Y
6.5
Industry
13.9
More Details
7.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.8
vs History
34
vs Industry
41
Median 3Y
6.6
Median 5Y
6.5
Industry
17.5
More Details
7.3
EV/OCF
EV/OCF
Enterprise Value to OCF
7.3
vs History
71
vs Industry
42
Median 3Y
11.2
Median 5Y
10.4
Industry
16.4
More Details
7.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
7.7
vs History
71
vs Industry
32
Median 3Y
11.5
Median 5Y
10.7
Industry
18.1
More Details
3.7
EV/IC
EV/IC
Enterprise Value to IC
3.7
vs History
19
vs Industry
23
Median 3Y
2.9
Median 5Y
2.5
Industry
1.9
More Details

Multiples Across Competitors

VLS Competitors Multiples
Vita Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Vita Life Sciences Ltd
ASX:VLS
119.5m AUD 1.6 13.2 7.8 7.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
741.6B USD 20.6 120.4 58.8 66.9
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.7 45.8 34.1 37.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
366.3B USD 4.3 9.5 11.7 15.2
US
Merck & Co Inc
NYSE:MRK
332.7B USD 5.4 143.1 35.6 58.1
UK
AstraZeneca PLC
LSE:AZN
188.7B GBP 5 37.7 174.5 278.4
CH
Novartis AG
SIX:NOVN
182.7B CHF 3.4 11.5 8.7 12.8
CH
Roche Holding AG
SIX:ROG
181.5B CHF 3.1 15.8 9 10.6
US
Pfizer Inc
NYSE:PFE
163B USD 2.9 -524 12.9 20.6
P/E Multiple
Earnings Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average P/E: 49.6
13.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
120.4
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.8
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.5
-20%
US
Merck & Co Inc
NYSE:MRK
143.1
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.7
168%
CH
Novartis AG
SIX:NOVN
11.5
15%
CH
Roche Holding AG
SIX:ROG
15.8
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -524
680%

See Also

Summary
VLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
VLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VLS stock valuation using valuation multiples.
Wall Street Estimates
VLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.